Article
Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Cancer chemotherapy and pharmacology - 1 Aug 2013
Chen Cui, Wang Fenghua, Wang Zhiqiang, Li Cong, Luo Huiyan, Liang Ying, An Xin, Shao Jianyong, Li Yuhong
Abstract excerpt
OBJECTIVES: We evaluated whether DNA repair gene polymorphisms had an effect on clinical outcomes in metastatic/recurrent nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based chemotherapy. MATERIALS AND METHODS: Clinical data of 101 patients with metastatic/recurrent NPC between 2004 and 2011 were reviewed. Five potentially functional polymorphisms (ERCC1 Asn118Asn, ERCC1 C8092A, XPD Lys751Gln,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
